• Economy
  • Editor’s Pick
Money Rise Today – Investing and Stock News
  • Investing
  • Stock
Editor's Pick

Dr. Marty Makary advances out of key committee in bid for FDA confirmation

by March 13, 2025
written by March 13, 2025

President Donald Trump’s nominee to lead the Food and Drug Administration (FDA), Dr. Marty Makary, passed a key committee vote 14-9 on Thursday morning, clearing the way for a full Senate vote on his nomination. 

If confirmed before the full Senate, Makary will work alongside the nominee for National Institute of Health (NIH) Director Dr. Jay Bhattacharya to achieve Secretary of Health and Human Services Robert F. Kennedy Jr.’s Make America Healthy Again agenda. 

The Senate Committee on Health, Education, Labor and Pensions(HELP) voted in favor of Makary’s confirmation following his committee hearing one week ago today. 

‘We now have a generational opportunity in American healthcare. President Trump and Secretary Kennedy’s focus on healthy foods has galvanized a grassroots movement in America. Childhood obesity is not a willpower problem, and the rise of early-onset Alzheimer’s is not a genetic cause. We should be, and we will, be addressing food as it impacts our health,’ Makary said last week. 

‘Thanks to the courage of President Trump and Secretary Kennedy, we now have a generational opportunity to usher in radical transparency to facilitate more cures, meaningful treatments and diagnostics at the FDA to help people take care of their own health,’ Makary added.

Makary was grilled by Democrats last week on vaccines, abortion, chronic illness and food safety. When repeatedly asked by Democratic senators on the committee whether he would revoke the approval process for Mifepristone, Makary said any decision on the abortion pill will come down to science. 

‘I have no preconceived plans on Mifepristone policy except to take a solid, hard look at the data and to meet with the professional career scientists who have reviewed the data at the FDA, and to build an expert coalition to review the ongoing data,’ he said. 

Makary, who advocated for natural immunity during the COVID-19 pandemic, flipped a question about vaccine processes around on Sen. Patty Murray, D-Wash., during his confirmation hearing, telling her to ask former President Joe Biden why he skipped a key step when it came to the COVID-19 booster. 

‘So, if you are confirmed, will you commit to immediately reschedule that FDA Vaccine Advisory Committee meeting to get the expert views?’ Sen. Patty Murray, D-Wash., asked Trump’s FDA pick. 

‘I would re-evaluate which topics deserve a convening of the advisory committee members on [Vaccines and Related Biological Products Advisory Committee] and which may not require a convening,’ Makary replied, adding that he was not a part of the decision. 

When asked again by Murray, he said: ‘Well, you can ask the Biden administration that chose not to convene the committee meeting for the COVID vaccine booster.’

He vowed during his committee hearing to lead his own Department of Government Efficiency (DOGE) investigations if confirmed. DOGE has terminated the employment of thousands of probationary HHS employees, including those at the FDA, since Trump took office. 

‘If confirmed, I will do my own independent assessment on personnel. I welcome input on efficiencies at the agency. At the same time, I want to make sure that the scientists and food inspectors and staff, central to the core mission of the agency, have all the resources they need to do their job well,’ Makary said last week. 

Makary has long been a critic of the FDA. He penned an opinion piece in 2021 that called for ‘fresh leadership at the FDA to change the culture at the agency and promote scientific advancement, not hinder it.’

Trump nominated Johns Hopkins School of Medicine professor, pancreatic surgeon and former Fox News medical contributor Dr. Marty Makary for FDA commissioner in November. 

‘I am very pleased to nominate Marty Makary MD, MPH, FACS, for FDA Commissioner,’ Trump said in a statement. ‘FDA has lost the trust of Americans, and has lost sight of its primary goal as a regulator. The Agency needs Dr. Marty Makary, a Highly Respected Johns Hopkins Surgical Oncologist and Health Policy Expert, to course-correct and refocus the Agency.’ 

Trump said that Makary will ‘work under the leadership of Robert F. Kennedy Jr. to, among other things, properly evaluate harmful chemicals poisoning our Nation’s food supply and drugs and biologics being given to our Nation’s youth, so that we can finally address the Childhood Chronic Disease Epidemic.’

Fox News Digital’s Julia Johnson contributed to this report.

This post appeared first on FOX NEWS
0 comment
0
FacebookTwitterPinterestEmail

previous post
FDA chief counsel who defended abortion pill access under Biden resigns two days into job
next post
Trump’s pick for NIH director clears committee, heads to full Senate vote

related articles

Trump denounces court’s ‘political’ tariff decision, calls on...

May 30, 2025

President Trump teases ‘last day, but not really’...

May 30, 2025

State Dept says DOGE’s changes will be permanent...

May 30, 2025

Jill Biden should have to answer for ‘cover...

May 29, 2025

DOGE staffing shakeup as Elon Musk hangs up...

May 29, 2025

Hawley urges DOJ probe of Chinese trucking company

May 29, 2025

Less than half of DOGE-terminated contracts can be...

May 29, 2025

Flashback: Top five wildest moments from Elon Musk’s...

May 29, 2025

Sen Ron Johnson suggests he may not run...

May 29, 2025

Justice Department tells American Bar Association it will...

May 29, 2025
Enter Your Information Below To Receive Free Trading Ideas, Latest News, And Articles.


Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

Latest News

  • The one characteristic of Reagan and Trump that sets them apart from other presidents

    July 28, 2024
  • Harris-Trump cash dash: Former president looks to flip script with fundraising swing in oil country

    September 28, 2024
  • DAVID MARCUS: In Scranton, even Kamala’s paid union supporters see writing on the wall

    October 26, 2024
  • DAVID MARCUS: Harris and Walz’s bizarre skit exposes double standard on race

    August 17, 2024
  • From NTPC to Tata Power: 5 power stocks to watch as India braces for extreme summer

    March 6, 2025

Popular Posts

  • 1

    Secret Service admits leaning on ‘state and local partners’ after claim it ignored Trump team’s past requests

    July 21, 2024
  • 2

    Elon and Vivek should tackle US funding for this boondoogle organization and score a multimillion dollar win

    December 4, 2024
  • 3

    Forex Profit Calculator: Maximize Your Trading Potential

    July 10, 2024
  • 4

    Five more House Democrats call on Biden to drop out, third US senator

    July 19, 2024
  • 5

    Biden calls to ‘lower the temperature’ then bashes Trump in NAACP speech

    July 17, 2024

Categories

  • Economy (829)
  • Editor's Pick (4,723)
  • Investing (624)
  • Stock (773)

Latest Posts

  • Chinese stocks surge on AI optimism, nearing three-year highs

    February 14, 2025
  • Rubio meets Saudi Arabian officials ahead of US-Russia talks expected to lay groundwork for Trump-Putin summit

    February 17, 2025
  • Putin ‘promises’ to ask Assad for help in finding Austin Tice following letter from mother

    December 19, 2024

Recent Posts

  • GOP rebels switch vote to Johnson after Trump’s 11th hour calls, pushing him over the finish line

    January 3, 2025
  • DAVID MARCUS: Trump should bring back Anno Domini and make ‘Common Era’ a woke footnote

    March 31, 2025
  • Unilever to cut 3,200 jobs in Europe by 2025 under new CEO’s growth plan

    July 12, 2024

Editor’s Pick

  • Some local Teamsters groups announce Harris endorsements after national union declines to do so

    September 21, 2024
  • DNI Gabbard refers intel officials to DOJ for prosecution over alleged leaks of classified information

    April 23, 2025
  • UK Stock Market News: FTSE 100 And FTSE 250 Plummeted

    July 24, 2024
  • About us
  • Contacts
  • Privacy Policy
  • Terms & Conditions

Disclaimer: moneyrisetoday.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2025 moneyrisetoday.com | All Rights Reserved

Money Rise Today – Investing and Stock News
  • Economy
  • Editor’s Pick
Money Rise Today – Investing and Stock News
  • Investing
  • Stock